Liang Weiting, Guo Zhijun, Zhang Yunhui, Yang Ning, Guo Chenchen, Liu Tao, Huang Hongbing, Chen Zhuojia
Department of Pharmacy, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Department of Pharmacy, Heyou Meihe Hospital, Foshan, China.
Case Rep Oncol. 2024 Feb 27;17(1):361-369. doi: 10.1159/000535504. eCollection 2024 Jan-Dec.
Cadonilimab (AK104) is an innovative human programmed cell death-1 (PD-1)/cytotoxic T lymphocyte antigen-4 (CTLA-4) bispecific antibody. Compared with the combination therapy of PD-1 and CTLA-4 blockers, less cellular toxicity of cadonilimab was significantly manifested. As one of the characteristic adverse effects of cadonilimab, infusion-related reactions (IRRs) represent fever, chills, rash, decreased blood pressure, and other symptoms.
Here, we documented seven cases of IRRs after the administration of cadonilimab. The symptoms of IRRs were relieved after the discontinuation of cadonilimab and the administration of diphenhydramine, dexamethasone, and cimetidine. Notably, 3 patients were able to tolerate the subsequent cadonilimab therapy under the pretreatment.
In this study, we discovered that cadonilimab-related IRRs might be lessened or prevented by administering medication and the proper pretreatment and lowering the infusion rate.
卡度尼利单抗（AK104）是一种创新型人程序性细胞死亡蛋白1（PD-1）/细胞毒性T淋巴细胞相关抗原4（CTLA-4）双特异性抗体。与PD-1和CTLA-4阻断剂联合治疗相比，卡度尼利单抗的细胞毒性明显较低。作为卡度尼利单抗的特征性不良反应之一，输液相关反应（IRR）表现为发热、寒战、皮疹、血压下降等症状。
在此，我们记录了7例使用卡度尼利单抗后发生IRR的病例。停用卡度尼利单抗并给予苯海拉明、地塞米松和西咪替丁后，IRR症状得到缓解。值得注意的是，3例患者在预处理下能够耐受后续的卡度尼利单抗治疗。
在本研究中，我们发现通过给药、适当的预处理和降低输液速度，可减轻或预防卡度尼利单抗相关的IRR。
